VCKA News and Press, Vickers Vantage Corp. I From 04/04/22

ZTlido 53% year-over-year preliminary unaudited gross sales in March 2022 Select payor accounts representing approximately 200 million of the over 300 million covered lives across the United States PALO ALTO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (&...

PALO ALTO, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-op...

Thoma Bravo is acquiring Anaplan for $10.7 billion or $66 per share in cash. Thoma Bravo agreed to pay 18 times trailing sales and 14 times Jan 2023 expected revenue of $746 million. Mill Road Capital urges Big Lots to sell itself. For further details see: Merger Arbitra...

Scilex Holding, a subsidiary of Sorrento Therapeutics (SRNE +1.2%), will go public through a combination with SPAC Vickers Vantage Corp. I (NASDAQ:VCKA). The combined company expected to have a pro forma equity value post-money of ~$1.6B. The transaction is expected to close in Q3 and shares ...

SP-102 (SEMDEXA™), with 401 patients enrolled in the C.L.E.A.R. trial (Corticosteroid Lumbosacral Epidural Analgesia in Radiculopathy), experienced a rapid onset of pain relief, measured by Numeric Pain Rating Scale of average daily pain in the affected leg, with highly statistical...

Combined company expected to have a pro forma equity value post-money of approximately $1.64 billion, subject to potential adjustment, and with up to $140 million in expected gross proceeds before expenses, assuming no redemptions from Vickers Vantage Corp. I’s existing public shar...

NEW YORK, NY, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Vickers Vantage Corp. I (Nasdaq: VCKAU, VCKA, VCKAW) (“Vickers” or the “Company”), a Cayman Islands exempted company, announced today that it has extended the time it has to consummate an initial business ...

Scilex Holding Company, a commercial-stage, non-opioid biopharmaceutical pain management company, announces highly significant positive top-line results from its Phase 3 SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R Program for its novel, non-opioid, corticosteroid formulation, injecta...

Scilex Holding Company (Scilex) a subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), and Vickers Vantage Corp I (Nasdaq: VCKA) announce signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Scilex of approximately $1...

SINGAPORE, June 01, 2021 (GLOBE NEWSWIRE) -- VICKERS VANTAGE CORP. I (NASDAQ: VCKA) (“Vickers” or the “Company”) , a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization o...